Spelling suggestions: "subject:"amyloid"" "subject:"l'amyloid""
1 |
Úloha m6A dráhy v regulaci kognitivních funkcí u potkanů v modelech Alzheimerovy choroby a kalorické restrikce / The role of m6A pathway in regulation of cognitive function in a rat model of Alzheimer's disease and caloric restrictionPohanová, Petra January 2019 (has links)
Reversible adenosine methylation (N6-methylation; m6A) at the RNA level was described in connection to the regulation of RNA fate. The N6-methyladenosine pathway is important for cognitive function and mechanisms related to memory, including the regulation of adult neurogenesis and synaptic plasticity. The objective of this study was to test the hypothesis that a decreased activity of the RNA-demethylase FTO is associated with improved cognitive function in rats. The RNA-demethylase FTO is a key regulator of the m6A pathway. In this study, we administered MO-I-500, a pharmacological inhibitor of FTO in TgF344-AD transgenic rats, which resulted in an improvement of spatial cognition. We further investigated the cognitive enhancement induced by a caloric restriction as a possible compensatory mechanism of cognitive disorders and its effect on the proteins regulating the N6-methyladenosine pathway. Long-term caloric restriction ameliorated cognitive functions and led to changes in the expression of the major proteins controlling the m6A pathway (FTO, METTL3) which are consistent with the aforementioned hypothesis. Although we do not know the exact mechanism of action, these findings support the hypothesis that m6A pathway regulators, such as the FTO demethylase, may be a promising molecular target for...
|
2 |
Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice / APPトランスジェニックマウスにおいて、運動は食事改善よりも高脂肪食によるAβの沈着および学習記憶の悪化を改善するMaesako, Masato 24 March 2014 (has links)
京都大学 / 0048 / 新制・課程博士 / 博士(人間健康科学) / 甲第18194号 / 人健博第11号 / 新制||人健||1(附属図書館) / 31052 / 京都大学大学院医学研究科人間健康科学系専攻 / (主査)教授 細田 公則, 教授 高桑 徹也, 教授 任 和子 / 学位規則第4条第1項該当 / Doctor of Human Health Sciences / Kyoto University / DFAM
|
3 |
Pathologische Veränderungen im Thalamus in einem Tiermodell für die Alzheimer-KrankheitFlohr, Johann-Christian Antonius 11 October 2010 (has links)
No description available.
|
4 |
Inflammatory cytokines and NFκB in Alzheimer’s diseaseFisher, Linda January 2006 (has links)
<p>Alzheimer’s disease is the most common form of dementia. It is a neurodegenerative disorder characterized by extracellular senile plaques and intracellular neurofibrillary tangles. The main constituent of the senile plaques is the neurotoxic β-amyloid peptide. Surrounding the senile plaques are activated astrocytes and microglia, believed to contribute to neurotoxicity through secretion of proinflammatory cytokines, like interleukin-1β and interleukin-6. For many inflammatory actions, including the cytokine induction in glial cells, the transcription factor NFκB plays a key role. This suggests that therapeutical strategies aimed to control the development of Alzheimer’s disease could include administration of drugs that hinder NFκB activation.</p><p>The major aim of this thesis was to examine the effects of β-amyloid together with interleukin-1β on cytokine expression as well as NFκB activation in glial cells. The possibility to block NFκB activation, and downstream effects like interleukin-6 expression, by using an NFκB decoy was investigated. The possibility to improve the cellular uptake of the decoy by linking it to a cell-penetrating peptide was also investigated.</p><p>The results obtained provide supportive evidence that inflammatory cytokines are induced by β-amyloid, and that they can indeed potentiate its effects. The results further demonstrate that by blocking NFκB activation, the induction of interleukin-6 expression can be inhibited. By using an improved cellular delivery system, the uptake of the NFκB decoy and hence the downstream cytokine inhibition could be increased. In conclusion, these results demonstrate the possibility to decrease the inflammatory reactions taken place in Alzheimer’s disease brains, which may ultimately lead to a possible way of controlling this disorder.</p>
|
5 |
Inflammatory cytokines and NFκB in Alzheimer’s diseaseFisher, Linda January 2006 (has links)
Alzheimer’s disease is the most common form of dementia. It is a neurodegenerative disorder characterized by extracellular senile plaques and intracellular neurofibrillary tangles. The main constituent of the senile plaques is the neurotoxic β-amyloid peptide. Surrounding the senile plaques are activated astrocytes and microglia, believed to contribute to neurotoxicity through secretion of proinflammatory cytokines, like interleukin-1β and interleukin-6. For many inflammatory actions, including the cytokine induction in glial cells, the transcription factor NFκB plays a key role. This suggests that therapeutical strategies aimed to control the development of Alzheimer’s disease could include administration of drugs that hinder NFκB activation. The major aim of this thesis was to examine the effects of β-amyloid together with interleukin-1β on cytokine expression as well as NFκB activation in glial cells. The possibility to block NFκB activation, and downstream effects like interleukin-6 expression, by using an NFκB decoy was investigated. The possibility to improve the cellular uptake of the decoy by linking it to a cell-penetrating peptide was also investigated. The results obtained provide supportive evidence that inflammatory cytokines are induced by β-amyloid, and that they can indeed potentiate its effects. The results further demonstrate that by blocking NFκB activation, the induction of interleukin-6 expression can be inhibited. By using an improved cellular delivery system, the uptake of the NFκB decoy and hence the downstream cytokine inhibition could be increased. In conclusion, these results demonstrate the possibility to decrease the inflammatory reactions taken place in Alzheimer’s disease brains, which may ultimately lead to a possible way of controlling this disorder.
|
6 |
Die Beeinflussung der β-Amyloid-Belastung in einem transgenen Mausmodell des Morbus Alzheimer durch Borna-Disease-Virus (BDV)-induzierte InflammationReimers, Christine 18 June 2008 (has links) (PDF)
Bei der Alzheimerschen Erkrankung handelt es sich um eine progressiv verlaufende, neurodegenerative Erkrankung, die die häufigste Form altersbedingter, kognitiver Dysfunktionen des Menschen darstellt. Sie ist pathomorphologisch durch eine fortschreitende Formation von amorphen und kompakten extrazellulären Amyloid-Ablagerungen (Plaques) sowie durch die Ausbildung intrazellulärer neurofibrillärer Bündel charakterisiert. Die Oligomerisierung und die Aggregation von β-Amyloid1-42-Peptiden zu fibrillären Plaques und davon ausgehende neurodegenerative Veränderungen führen zu einer unspezifischen Aktivierung von Mikrogliazellen und zu Entzündungsprozessen im ZNS. Diese Antigen-unspezifische Form der Mikroglia-Aktivierung ist neurotoxisch und fördert daher die Neurodegeneration im Verlauf der Alzheimerschen Erkrankung. Mikroglia-Aktivierung ist allerdings nicht generell neurotoxisch, da es verschiedene, in der vorliegenden Arbeit diskutierte Arten von mikroglialer Aktivierung mit jeweils unterschiedlichen – neurotoxischen bis hin zu neuroprotektiven - Auswirkungen gibt. Das Ziel dieser Arbeit war es, die mikrogliale Aktivierung in einem Mausmodell des Morbus Alzheimer zu modulieren und die resultierenden Effekte zu charakterisieren. Für die Modulation der mikroglialen Aktivierung wurde die subklinische Infektion mit dem neurotropen Borna Disease Virus (BDV) genutzt. Um den Einfluss der veränderten mikroglialen Aktivierung auf die zerebrale β-Amyloid-Belastung zu untersuchen, wurden swAPP-transgene Mäuse der Linie Tg2576 verwendet, die die schwedische Mutationsvariante des humanen app überexprimieren. Diese Mäuse produzieren humane β-Amyloid-Peptide, die sich mit zunehmendem Alter zu Plaques formieren. Transgene Mäuse wurden in drei Altersgruppen (11, 13,5 und 18 Monate) BDV-infiziert. Vier Wochen später wurden im Gehirn der Mäuse immunhistochemisch Lymphozyteninfiltration, Astroglia- und Mikroglia-Aktivierung untersucht. Die zerebrale βA-Belastung dieser BDV-infizierten Mäuse wurde mittels βA1-42-Immunhistochemie und Thioflavin-S-Markierung histometrisch quantifiziert und mit nicht infizierten, transgenen Kontrollmäusen verglichen. Auch eine biochemische Analyse der βA1-40- und βA1-42-Peptide mittels ELISA wurde vorgenommen. Zu keinem Zeitpunkt wurde eine klinisch manifeste BDV-Erkrankung registriert; die BDV-infizierten Mäuse blieben klinisch unauffällig. βA-Ablagerungen allein waren nur bei massiver Formation in der Lage, einzelne Mikroglia-zellen zu aktivieren. Erst die intrazerebrale BDV-Infektion induzierte vorrangig CD4-T-lymphozytäre Infiltrationen sowie eine deutliche BDV-spezifische Aktivierung der Mikroglia-zellen, die vier Wochen p.i. maximal ausgeprägt waren. Es lag eine positive lokale und graduelle Korrelation zwischen CD4-T-Lymphozyteninfiltrationen und Mikroglia-Aktivierung in den Gehirnen BDV-infizierter Mäuse vor. Bis auf eine Untersuchungsgruppe wurde keine nachweisbare Reaktion der Astroglia - weder auf die BDV-Infektion, noch auf die βA-Ablagerungen - registriert. In allen untersuchten Altersgruppen wurde ein tendenziell reduzierter βA-Gehalt in den Gehirnen der BDV-infizierten Tiere gegenüber den nicht infizierten Kontrolltieren registriert. Diese βA-Reduktion nach BDV-Infektion war in der Altersgruppe 13,5 Monate am deutlichsten ausgeprägt, wo die βA-Belastung der BDV-infizierten Tiere in vielen untersuchten Arealen signifikant geringer war als die der Kontrolltiere. Eine lokale Korrelation zwischen Mikroglia-Aktivierung und βA-Reduktion wurde nicht nachgewiesen. In zahlreichen untersuchten Hirnarealen aller drei Altersgruppen war der Anteil von vaskulär lokalisiertem β-Amyloid in den Gehirnen der BDV-infizierten Mäuse gegenüber den nicht infizierten Kontrollmäusen signifikant erhöht. Schlussfolgerungen: 1) In unserem Mausmodell führt die BDV-Infektion zu einer Modulation der Mikroglia-Aktivierung. 2) Die Korrelation der Mikroglia-Aktivierung mit viral bedingter T-Zellinfiltration und erhöhter Zytokinexpression deutet auf adaptive, T-Zell-vermittelte Modulation als Induktor dieser Aktivierung. 3) Die BDV-induzierte Mikroglia-Aktivierung führt zu einer: a) β-Amyloid-Reduktion, an der vermutlich von spezifisch aktivierten Mikrogliazellen ausgehende Clearance-Mechanismen beteiligt sind. b) β-Amyloid-Umverteilung vom Parenchym zu den Gefäßen, vermutlich, um den βA-Abtransport über das Gefäßsystem zu realisieren, wobei Amyloid-Einlagerungen in die Gefäßwände möglich sind. 4) Die viral induzierte Mikroglia-Aktivierung hängt sowohl vom Alter als auch von möglicher Voraktivierung der Zellen ab; altersbedingte Dysfunktionalität der Mikroglia ist eine potentielle Ursache der geringeren β-Amyloid-Clearance in der Altersgruppe 18 Monate. 5) Die Modulation der Mikroglia-Aktivierung ist prinzipiell möglich und führt zu potentiell positiven Effekten. 6) Dieses Modell ist zur Untersuchung der Modulation mikroglialer Aktivierung über adaptive Mechanismen geeignet. / Alzheimer´s Disease (AD) is a progressive neurodegenerative disorder and the most common form of age-related cognitive failure in humans. Pathomorphologically, it is characterized by a progressive accumulation of amorphous and compact extracellular amyloid-β deposits (plaques) as well as intracellular neurofibrillary tangles. Oligomerization and aggregation of amyloid-β1-42, its formation of fibrillary deposits as well as associated neurodegenerative changes lead to an unspecific activation of microglial cells and to inflammatory processes in the CNS. This unspecific form of microglial activation is neurotoxic and enhances neurodegeneration in the course of Alzheimer´s Disease. However, microglial activation is not neurotoxic per se, since there are various types of microglial activation that are being discussed in this study; the different activation types have varying effects reaching from neurotoxic to neuroprotective. The aim of the study was to modify microglial activation in a mouse model of Morbus Alzheimer and to characterize the resulting effects. For the modulation of microglial activation, we used the subclinic infection with the neurotropic Borna Disease Virus (BDV). In order to study the impact of the modulated microglial activation on the cerebral amount of beta-amyloid material, we used swAPP-transgenic Tg2576 mice, which overexpress the Swedish mutation variant of the human APP. These mice produce human amyloid β peptides that form amyloid plaques upon aging. We infected transgenic mice intracerebrally with BDV at different ages (11, 13,5 and 18 months old) and investigated brain-sections of these mice four weeks later by means of immunohistochemistry with regard to lymphocytic infiltrations, astroglial and microglial activation. The amount of amyloid β in the brains of BDV-infected mice was compared to that of non-infected, transgenic mice. The investigation of the cerebral amyloid β load was realized immunohistochemically by using an anti-Aβ1-42-antibody as well as by means of Thioflavin-S fluorescence technique followed by histometric quantification. Additionally, a biochemical analysis of Aβ1-40 and Aβ1-42 peptides was done using an ELISA-kit. A clinically apparent BDV-disorder could not be seen at any stage; BDV-infected mice remained free of BDV symptoms. Only massive amyloid-β deposits were able to independently induce activation of single microglial cells. Intracerebral BDV-infection caused marked infiltrations of primarily CD4-T-lymphocytes as well as a prominent specific microglial activation, which reached maximum levels four weeks p.i. A positive local and gradual correlation of CD4-T-lymphocytes and microglial activation was registrated in the brains of BDV-infected mice. Except one age group, neither BDV-infection nor amyloid-β deposits induced a detectable reaction of astrocytes. In all investigated age groups, a reduced amount of amyloid-β could be measured in the brains of BDV-infected mice compared to non-infected control mice. This Aβ reduction after BDV-infection was most prominent in the age group 13,5 months, where Aβ-load of BDV-infected mice was significantly decreased in many brain areas compared to that of control mice. A local correlation of microglial activation and Aβ reduction could not be observed. Several brain areas in all three age groups showed a significantly higher amount of vascular amyloid-β in the brains of BDV-infected mice compared to those of non-infected controls. Conclusions: 1) In our mouse model, BDV-infection leads to a modulation of microglial activation. 2) The correlation of microglial activation with viral-induced infiltrations of T cells and with upregulated cytokine expression suggests an adaptive, T cell-induced modulation as trigger of this acivation. 3) BDV-specific microglial activation leads to: a) Reduced cerebal amyloid-β load, possibly realized by clearance mechanisms of activated microglial cells. b) Redistribution of amyloid-β from the parenchyma to the vessels, possibly in order to clear the amyloidogenic material via the vasculature. During these processes, amyloid deposition in the walls of the cerebral blood vessels is possible. 4) Viral-induced microglial activation depends on the cell´s age and possible pre-activation; dysfunctional changes in microglia might be a cause for the less effective Aβ-clearance observed in the age group 18 months. 5) In principle, modulation of microglial activation is possible and leads to potential beneficial effects. 6) This study displays a proper model for investigations of the modulation of microglial activation via adaptive mechanisms.
|
7 |
The Effects of β-Amyloid on α7 Nicotinic Acetylcholine Receptors Expressed in Xenopus OocytesAnderson, Malia L. 06 July 2011 (has links) (PDF)
The exact mechanism and progression of Alzheimer's disease (AD) at present is not fully understood. In patients suffering from AD, damage to the hippocampal region and impairment of learning and memory is present. It is also known that a buildup of β-amyloid plaques occur in AD patients and that β-amyloid interacts with some subtypes of neuronal nicotinic acetylcholine receptors (neuronal nAChRs). These receptors are composed of five subunits. The most prevalent nAChR subunit composition through the brain as a whole is α7. Previous data produced from our lab suggests that α7 nAChRs are also one of the most prevalent subunits expressed by interneurons within the hippocampal region, a part of the brain known to be involved in memory and learning. It is hypothesized that one mechanism through which learning and memory becomes impaired in AD is through the interaction of β-amyloid with these nAChRs. It has previously been established that nanomolar amounts of β-amyloid inhibit the peak currents of α7 nAChRs. However, concentrations of β-amyloid in the picomolar range, in some studies show an activation of α7 nAChRs, while other studies no activation is seen. In this experiment we show that human α7 subunit nAChRs are not activated by β-amyloid42 at 1 pM- 30 nM concentrations. We also show that short, seven-second applications of β-amyloid interact with the α7 nAChRs to alter the kinetics of the channel, however, the exact mechanism and pattern by which it effects the channel is still unclear.
|
8 |
Molecular studies of the γ-secretase complex activity and selectivity towards the two substrates APP and NotchBakir, Ilyas January 2010 (has links)
<p>Alzheimer Disease (AD) is the most common neurodegenerative disorder in the world. One of the neuropathological hallmarks of AD is the senile plaques in the brain. The plaques are mainly composed of the amyloid β (Aβ) peptide. Aβ is generated from the amyloid precursor protein, APP, when it is first cleaved by the β-secretase and subsequently the γ-secretase complex. The γ-secretase complex cleaves at different sites, called γ and ε, where the γ-cleavage site generates Aβ peptides of different lengths and ε-cleavage generates the APP intracellular domain (AICD). The two major forms of Aβ is 40 and 42 amino acids long peptides, where the latter is more prone to aggregate and is the main component in senile plaques. The γ-secretase complex is composed of four proteins; Pen-2, Aph-1, nicastrin and presenilin (PS). The PS protein harbours the catalytic site of the complex, where two aspartate residues in position 257 and 385 (Presenilin 1 numbering) are situated. Most Familial AD (FAD) mutations in the PS gene cause a change in the γ-cleavage site, leading to a shift from producing Aβ40 to the longer more toxic variant Aβ42. Frequently, this often leads to impairments of the AICD production. Another substrate for the γ-secretase complex is Notch. It is important to maintain the Notch signaling since an intracellular domain (NICD) is formed after cleavage by the γ-secretase complex in the membrane (S3-site) and this domain is involved in transcription of genes important for cell fate decisions.</p><p>It has been reported that certain APP luminal juxtamembrane mutations could drastically alter Aβ secretion, however their effect on AICD production remains unknown. In this study we want to analyse wether the juxtamembrane region is important for the AICD production. To gain more insight into the luminal juxtamembrane function for γ-secretase-dependent proteolysis, we have made a juxtamembrane chimeric construct. A four-residue sequence preceding the transmembrane domain (TMD) of APP (GSNK), was replaced by its topological counterpart from the human Notch1 receptor (PPAQ). The resulting chimeric vector C99GVP-PPAQ and the wildtype counterpart were expressed in cells lacking PS1 and PS2 (BD8) together with PS1wt. We observed that the chimeric construct did not alter production of AICD when using a cell based luciferase reporter gene assay monitoring AICD production. We also introduced a PS1 variant lacking a big portion of the large hydrophilic loop, PS1∆exon10, since our group has previously observed that this region affect Aβ production<sup>143</sup>. We found that the absence of the large hydrophilic loop in PS1 gave a 2-fold decrease in AICD-GVP formation from C99GVPwt compared to PS1wt. The activity of PS1wt and PS1Δexon10 using C99GVP-PPAQ as a substrate gave similar result as the C99GVPwt substrate, i.e. a 2-fold decrease in AICD-GVP formation when comparing PS1Δexon10 with PS1wt. From this data we therefore suggest that the four residues in the juxtramembrane domain (JMD) (GSNK) is not altering ε-cleavage of APP when changed to Notch1 counterpart, PPAQ. Furthermore, we also show that the 2-fold decrease in AICD-production by the PS1Δexon10 molecule is not changed between the two substrates C99GVPwt and C99GVP-PPAQ. This indicates that the luminal region of APP is not directly involved in the ε-site processing. If the luminal region is affecting processing in the γ-cleavage sites, remains however to be investigated.</p>
|
9 |
Molecular studies of the γ-secretase complex activity and selectivity towards the two substrates APP and NotchBakir, Ilyas January 2010 (has links)
Alzheimer Disease (AD) is the most common neurodegenerative disorder in the world. One of the neuropathological hallmarks of AD is the senile plaques in the brain. The plaques are mainly composed of the amyloid β (Aβ) peptide. Aβ is generated from the amyloid precursor protein, APP, when it is first cleaved by the β-secretase and subsequently the γ-secretase complex. The γ-secretase complex cleaves at different sites, called γ and ε, where the γ-cleavage site generates Aβ peptides of different lengths and ε-cleavage generates the APP intracellular domain (AICD). The two major forms of Aβ is 40 and 42 amino acids long peptides, where the latter is more prone to aggregate and is the main component in senile plaques. The γ-secretase complex is composed of four proteins; Pen-2, Aph-1, nicastrin and presenilin (PS). The PS protein harbours the catalytic site of the complex, where two aspartate residues in position 257 and 385 (Presenilin 1 numbering) are situated. Most Familial AD (FAD) mutations in the PS gene cause a change in the γ-cleavage site, leading to a shift from producing Aβ40 to the longer more toxic variant Aβ42. Frequently, this often leads to impairments of the AICD production. Another substrate for the γ-secretase complex is Notch. It is important to maintain the Notch signaling since an intracellular domain (NICD) is formed after cleavage by the γ-secretase complex in the membrane (S3-site) and this domain is involved in transcription of genes important for cell fate decisions. It has been reported that certain APP luminal juxtamembrane mutations could drastically alter Aβ secretion, however their effect on AICD production remains unknown. In this study we want to analyse wether the juxtamembrane region is important for the AICD production. To gain more insight into the luminal juxtamembrane function for γ-secretase-dependent proteolysis, we have made a juxtamembrane chimeric construct. A four-residue sequence preceding the transmembrane domain (TMD) of APP (GSNK), was replaced by its topological counterpart from the human Notch1 receptor (PPAQ). The resulting chimeric vector C99GVP-PPAQ and the wildtype counterpart were expressed in cells lacking PS1 and PS2 (BD8) together with PS1wt. We observed that the chimeric construct did not alter production of AICD when using a cell based luciferase reporter gene assay monitoring AICD production. We also introduced a PS1 variant lacking a big portion of the large hydrophilic loop, PS1∆exon10, since our group has previously observed that this region affect Aβ production143. We found that the absence of the large hydrophilic loop in PS1 gave a 2-fold decrease in AICD-GVP formation from C99GVPwt compared to PS1wt. The activity of PS1wt and PS1Δexon10 using C99GVP-PPAQ as a substrate gave similar result as the C99GVPwt substrate, i.e. a 2-fold decrease in AICD-GVP formation when comparing PS1Δexon10 with PS1wt. From this data we therefore suggest that the four residues in the juxtramembrane domain (JMD) (GSNK) is not altering ε-cleavage of APP when changed to Notch1 counterpart, PPAQ. Furthermore, we also show that the 2-fold decrease in AICD-production by the PS1Δexon10 molecule is not changed between the two substrates C99GVPwt and C99GVP-PPAQ. This indicates that the luminal region of APP is not directly involved in the ε-site processing. If the luminal region is affecting processing in the γ-cleavage sites, remains however to be investigated.
|
10 |
Polymeric nanoparticles as original theranostic approach for alzheimer‟s disease / Nanoparticules polymériques pour le diagnostic et la thérapie de la maladie d'AlzheimerBrambilla, Davide 11 January 2012 (has links)
La preuve de concept d‟une approche theranostique pour la Maladie de Alzheimer basée sur les nanotechnologies a été explorée. Des nouvelles nanoparticules polymeriques fluorescentes on été conçus, et leur internalisation et aptitude à traverser un nouveau modèle in vitro de barrière hémato-encéphalique humaine on été étudiées en détails. Une petite librairie de nanoparticules polymerique a été préparés, et leur capacité de capturer le peptide β-Amyloïde1-42, considéré comme une des principales causes de la dégénérescence neuronale, a été évaluées et quantifiées en utilisant une méthode expressément conçus. / The proof of concept of an original nanotechnology-based theranostic approach for Alzheimer‟s disease has been explored. Novel fluorescently tagged nanoparticles have been designed and employed for internalization and transcytosis studies across a recently developed human in vitro blood-brain barrier model. A small library of polymeric nanoparticles have been designed and their ability to capture the Amyloid β1-42 peptide, considered one of the causes of the Alzheimer‟s disease, has been investigated and quantified using an on purpose designed method.
|
Page generated in 0.0437 seconds